What will the average number of measles cases be during Trump's term?

**Stage 1 — Blind analysis (ignore market price).**

Assumption: the market's implicit binary question is whether the *four-year average annual* U.S. measles cases during the Trump administration (2025–2028) will exceed the recent benchmark of ~205 cases/year (the figure the prompt calls the most useful benchmark). Under that interpretation, we already have two full years (2025 and 2026) with >2,000 reported cases each. Even if 2027 and 2028 return close to the recent baseline (~200) or to pre-2020 levels (~60), the arithmetic average across four years will remain far above 205. Example arithmetic: (2,000 + 2,000 + 200 + 200)/4 = 1,100. Therefore, under straightforward counting conventions, the probability the 4-year average exceeds 205 is effectively near-certain.

Key factual inputs (treated as given): - 2025: >2,000 cases (reported). 2026: >2,000 cases (ongoing, already >2,000). - Recent multi-year average cited at ~205/year; earlier baseline 2000–2010 average ~60/year. - The market question likely counts completed calendar years (2025–2028) rather than partial-year projections; if partial-year inclusion were used instead, it would only reduce certainty if the market excluded the high-count years entirely, which is not consistent with the prompt interpretation.

Independent probability conclusion (Stage 1): Given the observed counts for 2025 and 2026, and realistic bounds for 2027–2028 (even extremely optimistic public-health responses that sharply reduce cases), the 4-year average almost certainly exceeds 205/year. My independent probability for "Yes (average >205)" is 98%.

**Stage 2 — Market calibration (examine current prices and explain discrepancies).**

Observed market price: Yes = 0.31, No = 0.69. This stands in strong conflict with the Stage 1 independent assessment. Possible reasons for the market price being low:

- *Wording / threshold ambiguity*: Traders may be interpreting the contract as asking whether the average will exceed a *much higher* threshold (e.g., >2,000/year or >1,000/year) rather than the ~205 benchmark noted in the prompt. If the contract's Yes means "average above X" for some large X, the low Yes price would make sense. The prompt’s benchmark numbers suggest 205 is the obvious cutoff, but markets sometimes embed a different numeric line in the contract text; if so, my independent assessment should be recalibrated to that actual threshold.

- *Averaging convention / included years ambiguity*: Some traders may believe the contract uses only completed years before a certain cut (e.g., excluding 2025 or 2026) or averages differently (median vs mean), or that it counts only calendar years fully inside the term in a different way. If a market participant thinks the averaging window excludes one or both high-count years, they could rationally price Yes lower.

- *Data revision risk / surveillance corrections*: Some traders may be pricing in the possibility that the >2,000 counts are later revised downward substantially because of case reclassification, reporting errors, deduplication, or changes in surveillance definitions. Large downward revisions are possible but historically rare at the scale required to undo thousands of cases.

- *Tail risk beliefs and contrarian positioning*: The market could be dominated by participants expecting an extremely large suppression of measles in 2027–2028 (e.g., mass vaccination campaigns, travel restrictions, or other interventions) and assigning nontrivial probability to very low subsequent years—this could push the aggregate market probability downward.

Why I think the market is likely mispriced relative to the benchmark interpretation: - The arithmetic effect of two consecutive >2,000 years is overwhelmingly large relative to any plausible decline in the next two years; it would take implausibly low 2027 and 2028 totals (close to 0) to push the four-year mean below 205. - Data-revision scenarios sufficient to change the outcome would require systemic reclassification of thousands of cases to non-measles; while possible at small scales, wholesale downward reclassification of both years by an order of magnitude is historically unlikely.

Actionable implication: If the contract actually uses the ~205 cutoff and the market price is 0.31 for Yes, that appears to be a significant undervaluation of the true probability; buying Yes contracts would be a strong value trade. However, confirm contract text and averaging convention before acting—if the market uses a different numeric threshold, my independent probability would change and the apparent arbitrage could vanish.